Início
Mercados
Gráficos e ideias
Algo
Notícias
Market
Corretoras
Baixar
Calendário econômico
Sinais de Negociação
Terminal web
Heatmap
Pressione
/
para pesquisar: @user, $symbol, ...
Pesquisar
Login
Criar uma conta
Português
English
Русский
中文
Español
日本語
Deutsch
한국어
Français
Italiano
Türkçe
URGN
#2445
UroGen Pharma Ltd. Ordinary Shares
21.220
0
USD
+4.64%
Setor:
Cuidados de saúde
Base:
USD
Moeda do lucro:
USD
Faixa diária
Faixa anual
Mudança diária
+4.64%
Mudança mensal
+12.69%
Mudança em 6 meses
+11.68%
Mudança anual
+11.68%
Fechamento anterior
20.280
0
Abrir
21.220
0
Bid
Ask
Mínimo
21.220
0
High
21.220
0
Volume
100
Mercados
Ações
Cuidados de saúde
URGN
Abrir gráfico completo
Financials
Visão geral
Relatórios
Estatísticas
Trimestral
Ano
Valor
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
22.27 M
22.67 M
23.44 M
34.12 M
46.09 M
48.68 M
—
Valuation ratios
Enterprise value
348.49 M
171.21 M
244.66 M
522.55 M
441.4 M
1.15 B
3.31 B
Price to earnings ratio
—
—
-1.79
-4.29
-3.6
-7.34
-20.71
Price to sales ratio
—
—
3.52
6.45
5.86
11.93
37.73
Price to cash flow ratio
—
—
-2.25
-5.74
-4.72
-6.94
-23.5
Price to book ratio
—
—
-2.21
-6.73
-51.87
-10.68
24.82
Enterprise value to EBITDA ratio
-2.75
-1.87
-2.86
-6.6
-4.05
-8.17
-23.78
Profitability ratios
Return on assets %
-1.05
-0.93
-0.81
-0.57
-0.44
-0.77
-0.73
Return on equity %
-1.33
-13.17
1.23
1.57
14.41
1.46
2.02
Return on invested capital %
-1 304.03
-2 060.7
-1 538.17
-1 158.23
-1 526.09
-1 244.1
-1 789.5
Gross margin %
91.45
89.27
101.4
107.87
104.67
103.07
415.45
Operating margin %
-1 074.15
-192.11
-141.35
-96.38
-124.28
-132.21
-604.15
EBITDA margin %
-1 074.29
-190.38
-154.79
-116.84
-139.98
-149.57
-679.23
Net margin %
-1 088.94
-230.67
-196.33
-150.36
-162.92
-162.53
-735.25
Liquidity ratios
Quick ratio
5.3
4.9
5.21
5.24
5.81
3.65
16.9
Current ratio
5.39
5.11
5.39
5.42
6.01
4.01
17.78
Inventory turnover
—
—
0.19
0
—
—
—
Asset turnover
0.07
0.4
0.44
0.43
0.34
0.39
0.45
Solvency ratios
Debt to assets ratio
—
—
0.72
0.55
0.43
0.62
2.37
Debt to equity ratio
—
—
-1.09
-1.51
-13.91
-1.17
-6.21
Long term debt to total assets ratio
—
—
0.72
0.55
0.43
0.61
2.35
Long term debt to total equity ratio
—
—
-1.09
-1.51
-13.83
-1.16
-6.16
Per share metrics
Operating cash flow per share
—
—
-3.84
-2.65
-2.26
-3.38
-3.4
EBIT per share
—
—
-3.84
-2.78
-2.55
-2.94
-2.96
EBITDA per share
—
—
-3.8
-2.76
-2.54
-2.94
-2.96
Total debt per share
—
—
4.28
3.42
2.86
2.57
10.31
Cash per share
—
—
4.38
4.91
5.64
2.5
12.77
Net current asset value per share
—
—
5.65
5.87
6.44
3.87
16.5
Tangible book value per share
—
—
-3.92
-2.26
-0.21
-2.19
-7.53
Working capital per share
—
—
4.6
4.79
5.37
2.9
12.77
Book value per share
—
—
-3.92
-2.26
-0.21
-2.19
-7.53
Notícias
Zusduri da UroGen apresenta taxa de 72% livre de eventos em 24 meses
UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers
UroGen Pharma na Conferência TD Cowen: crescimento estratégico e inovação
UroGen Pharma at TD Cowen Conference: Strategic Growth and Innovation
Oppenheimer eleva preço-alvo das ações da UroGen Pharma para US$ 34 com base nas vendas de Zusduri
Oppenheimer raises UroGen Pharma stock price target to $34 on Zusduri sales
Oppenheimer reitera classificação das ações da UroGen Pharma com vendas fortes de Zusduri
Oppenheimer reiterates UroGen Pharma stock rating on strong Zusduri sales
UroGen Pharma fica abaixo das previsões de LPA e receita no 4º tri de 2025
Earnings call transcript: UroGen Pharma Q4 2025 misses EPS and revenue forecasts
Palantir and AeroVironment among market cap stock movers on Monday
Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates